High-throughput T cell receptor engineering by functional screening identifies candidates with enhanced potency and specificity

Authors:
Rodrigo Vazquez-Lombardi, Johanna S. Jung, Fabrice S. Schlatter, Anna Mei, Natalia Rodrigues Mantuano, Florian Bieberich, Kai-Lin Hong, Jakub Kucharczyk, Edo Kapetanovic, Erik Aznauryan, Cedric R. Weber, Alfred Zippelius, Heinz Laeubli, and Sai T. Reddy
In:
Source: Immunity
Publication Date: (2022)
Issue: 55: 1953-1966
Research Area:
Cancer Research/Cell Biology
Immunotherapy / Hematology
Regenerative medicine
Cells used in publication:
Jurkat-modified
Species: human
Tissue Origin:
Platform:
4D-Nucleofector® X-Unit
4D-Nucleofector® LV-Unit
Experiment

CRISPR-Cas9 genome editing
Transfection of TnT cells and Jurkat-derived cell lines was performed by electroporation using the 4D-Nucleofector device (Lonza) and the SE cell line kit (Lonza, #V4XC-1024). The day before transfection, cells were seeded at 2.5x105 cells ml-1 and cultured for 24 h. Prior to transfection, gRNA molecules were assembled by mixing 4µl of custom Alt-R crRNA (200 mM, IDT) with 4 µL of Alt-R tracrRNA (200 mM, IDT, #1072534), incubating the mix at 95°C for 5 min and cooling it to room temperature. For transfection of Cas9-negative cell lines, 2 µL of assembled gRNA molecules were mixed with 2 mL of recombinant SpCas9 (61 mM, IDT, #1081059) and incubated
for > 10 min at room temperature to generate Cas9 RNP complexes. Immediately prior to transfection, cells were washed twice in PBS and 1x10^6 cells were re-suspended in 100 µL of SE buffer. 1.5 µg of HDR template and 7 µL of assembled gRNA (or 4 µL of Cas9 RNP complexes) were added to the cell suspension, mixed and transferred into a 1 mL electroporation cuvette. Cells were electroporated using program CK116, topped-up with 1 mL of complete media and rested for 10 min prior to transfer into a 12-well plate. Alt-R HDR enhancer (IDT, #1081073) was added at a 30 mM final concentration and removed after 16 h of culture by centrifugation. HDR efficiency was assessed by flow cytometry on day 5 post-transfection. For transfections at the 20 µL scale (Lonza, #V4XC- 1032), cell numbers and reagent volumes were reduced 5-fold.

Combinatorial TCRA3 library screening

Combinatorial library HDR templates (20 µg) and CDR3B gRNA (10 nmol) were used to transfect 1x10^8 TnT cells using the 4D Nucleofector LV unit (Lonza, #AAF-1002L).

Primary T cell reconstitution with transgenic TCRs
For generation of CRISPR TCR-T cells, T cells were activated with anti-CD3/anti-CD28 tetrameric antibody complexes (Stemcell Technologies, #10971) on days 1 and 13 of culture and expanded every 3-4 days. Transfection of primary T cells with Cas9 RNP complexes and TCRba HDR templates was performed 3-4 days following activation using the 4D-Nucleofector and a 20 µL format P3 Primary Cell kit (Lonza, V4XP-3032). Briefly, 1x10^6 primary CD8+ T cells were transfected with 1 mg of HDR template, 1 µl of TRAC Cas9 RNP complex and 1 µl of TRBC1/2 Cas9 RNP complex using the EO115 electroporation program (Cas9 RNP complexes = 50 µM gRNA, 30.5 µM recombinant SpCas9).

Abstract

A major challenge in adoptive T cell immunotherapy is the discovery of natural T cell receptors (TCRs) with high activity and specificity to tumor antigens. Engineering synthetic TCRs for increased tumor antigen recognition is complicated by the risk of introducing cross-reactivity and by the poor correlation that can exist between binding affinity and activity of TCRs in response to antigen (peptide-MHC). Here, we developed TCR-Engine, a method combining genome editing, computational design, and deep sequencing to engineer the functional activity and specificity of TCRs on the surface of a human T cell line at high throughput. We applied TCR-Engine to successfully engineer synthetic TCRs for increased potency and specificity to a clinically relevant tumor-associated antigen (MAGE-A3) and validated their translational potential through multiple in vitro and in vivo assessments of safety and efficacy. Thus, TCR-Engine represents a valuable technology for engineering of safe and potent synthetic TCRs for immunotherapy applications.